PMID- 31156248 OWN - NLM STAT- MEDLINE DCOM- 20190826 LR - 20190826 IS - 1997-7298 (Print) IS - 1997-7298 (Linking) VI - 119 IP - 2. Vyp. 2 DP - 2019 TI - [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab]. PG - 98-106 LID - 10.17116/jnevro20191192298 [doi] AB - This paper presents a case report of subtentorial progressive multifocal leukoencephalopathy (PML) in a 26-year-old female patient treated with natalizumab. The evolution of clinical features, neuroimaging data and treatment as well as the development of immune reconstitution inflammatory syndrome (IRIS) are described. This case emphasizes the importance to keep accurately the risk management plan during natalizumab treatment. This includes performing MRI scans in order to detect changes typical for PML at the earliest (preclinical) stage in time. FAU - Simaniv, T O AU - Simaniv TO AD - Research Center of Neurology, Moscow, Russia. FAU - Ivanova, M V AU - Ivanova MV AD - Research Center of Neurology, Moscow, Russia. FAU - Bryukhov, V V AU - Bryukhov VV AD - Research Center of Neurology, Moscow, Russia. FAU - Zakharova, M N AU - Zakharova MN AD - Research Center of Neurology, Moscow, Russia. LA - rus PT - Case Reports PT - Journal Article TT - Sluchai razvitiia progressiruiushchei mul'tifokal'noi leikoentsefalopatii subtentorial'noi lokalizatsii na fone terapii natalizumabom. PL - Russia (Federation) TA - Zh Nevrol Psikhiatr Im S S Korsakova JT - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova JID - 9712194 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Immunologic Factors) RN - 0 (Natalizumab) MH - Adult MH - Antibodies, Monoclonal, Humanized MH - Female MH - Humans MH - *Immune Reconstitution Inflammatory Syndrome MH - *Immunologic Factors/adverse effects MH - *Leukoencephalopathy, Progressive Multifocal/chemically induced MH - *Multiple Sclerosis/drug therapy MH - *Natalizumab/adverse effects MH - Neuroimaging OTO - NOTNLM OT - JC-virus OT - immune reconstitution inflammatory syndrome (IRIS) OT - monoclonal antibodies OT - multiple sclerosis OT - natalizumab OT - progressive multifocal leukoencephalopathy (PML) EDAT- 2019/06/04 06:00 MHDA- 2019/08/27 06:00 CRDT- 2019/06/04 06:00 PHST- 2019/06/04 06:00 [entrez] PHST- 2019/06/04 06:00 [pubmed] PHST- 2019/08/27 06:00 [medline] AID - 10.17116/jnevro20191192298 [doi] PST - ppublish SO - Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):98-106. doi: 10.17116/jnevro20191192298.